5-Trifluoromethyl-2'-deoxyuridine (F3dThd) was first synthesized in 1964 as a thymidine analog for the treatment of human neoplasias (7) . After little initial success, it was shown to be effective in combination with vincristine, papaverine, and cyclophosphamide in the treatment of childhood neuroblastoma (L. Helson, Proc. 67th Annu. Meet. Am. Assoc. Cancer Res. 17:236, 1976 ). F3dThd inhibits the growth of various mammalian cells in culture (13, 17) and some tumors in mice and is effective in the treatment of experimental herpes simplex virus type 1 (HSV-1) encephalitis in mice (5). Wellings et al. have reported F3dThd to be superior to 5-iodo-2'-deoxyuridine in the management of human ocular herpetic keratitis (18) .
In vitro investigations have demonstrated that F3dThd-5'-monophosphate (F3dThd-5'-P) inhibits mammalian thymidylate synthetase (14) , and F3dThd-5'-triphosphate (F3dThd-5'-PPP) competitively inhibits HeLa cell DNA polymerase and vaccinia viral DNA polymerase (15) . F3dThd-5'-PPP is also incorporated into cellular and viral DNA (15) . Studies on the pharmaceutical stability of F3dThd have demonstrated that the drug is hydrolyzed to 5-carboxy-2'-deoxyuridine (5-COOH-2'-dUrd) via a hydroxyl ion attack on the 5-trifluoromethyl group of the anionic and undissociated species (12) . The hydrolysis has been shown to follow first-order kinetics (12) . This communication describes the kinetics of hydrolysis of F3dThd at physiological pH, temperature, and ionic strength. The biological effects ofthe hydrolysis product are also compared with those of the parent compound.
MATERIALS AND METHODS
Cell culture. Eagle minimum essential medium (Grand Island Biological Co.
[GIBCO]) supplemented of penicillin per ml, and 50 ,ug of streptomycin per ml (MEM-C) was used for growth of HEp-2 monolayers and for toxicity testing. Eagle minimum essential medium for Spinner culture supplemented with 10% heatinactivated calf serum (GIBCO), 50 U of penicillin per ml, 50 [Lg of streptomycin per ml, and 0.075% Pluronic F68 (BASF Wyandotte, Wyandotte, Mich.) was used for propagation of stock HEp-2 cell cultures.
Virus. The Maclntyre strain of HSV-1 (ATCC VR-539) and the MS strain of HSV-2 (ATCC VR-540) were propagated in HEp-2 cells. Confluent HEp-2 monolayers were used to assay infectious virus (8) .
Incorporation (12) . The fmal absorbance of 5-COOH-2'-dUrd was measured at 272 nm in 0.1 N NaOH, and its concentration was determined by using an extinction coefficient of 7,800 M-' cm-2 (12 Sonifier cell disrupter equipped with a microtip for two 30-s bursts at a setting of 4, followed by centrifugation at 100,000 x g for 60 min. The temperature was maintained at 4°C throughout the preparation. The resulting supernatant was stored at -20°C and used as the source of HEp-2 dTk.
HSV-1 dTk preparations were obtained in a similar manner from HEp-2 cells which had been infected with HSV-1 at 2 plaque-forming units per cell for 12 to 24 h.
Determination of dTk activity. The dTk activity was measured by a modification of the diethylaminoethyl-cellulose disk method described by Bollum and Potter (2) orotidine, uridine, dThd, and deoxycytidine. The concentration of 5-COOH-2'-dUrd used throughout was 5.0 x 10-5 M. At 24-h intervals for 3 days, the medium was removed, and the cells were washed with PBS, treated with 0.1% trypsin, resuspended in MEM-C, and counted with a hemocytometer. Table 2 shows that no single compound reversed cytotoxicity completely. However, upon simultaneous addition of dThd, uridine, and deoxycytidine, 90% reversal of toxicity was achieved. Attempts at reversing toxicity with Ncarbamyl-DL-aspartic acid, dihydroorotic acid, or orotic acid were unsuccessful. These data suggest that 5-COOH-2'-dUrd inhibits de novo pyrimidine synthesis at the steps preceding uridine 5'-phosphate formation in the de novo pyrimidine biosynthetic pathway (9) . The failure of orotic acid to reverse toxicity coupled with the partial reversal seen with orotidine suggest that cytotoxicity occurs by inhibition of orotate phosphoribosyl transferase.
Effect of 5-COOH-2'-dUrd on DNA and RNA synthesis. Further attempts to localize the reaction(s) inhibited by 5-COOH-2'-dUrd involved the incorporation of radioactive nucleic acid precursors into DNA and RNA. HEp-2 cells were incubated for 12 to 24 h with either [6-'4C]-orotic acid or [5,6-3H] uridine in the presence or absence of 50 ,uM 5-COOH-2'-dUrd. Cells were harvested, and DNA and RNA were examined for the incorporation of carbon 14 or tritium as described above.
These experiments showed that 5-COOH-2'-dUrd inhibited the incorporation of ['4C]orotic acid into RNA and DNA by 65 and 27%, respectively. It was also shown that 5-COOH-2'-dUrd did not alter the incorporation of [3H]uridine into RNA and DNA. These results further support the hypothesis that 5-COOH-2'-dUrd prevents the conversion of orotic acid to uridine 5'-phosphate via orotate phosphoribosyl transferase and orotidine 5'-phosphate decarboxylase.
Antiviral activity of 5-COOH-2'-dUrd. F3dThd has been shown to be a potent inhibitor of HSV replication both in vivo and in vitro and 5) a All compounds were added at the time cells were planted. 50 ,uM 5-COOH-2'-dUrd was used to establish cytotoxicity. Percent reversal was determined after 3 days of growth.
of vaccinia virus in vitro (5, 13). The product of F3dThd hydrolysis, 5-COOH-2'-dUrd, was tested for its antiviral effects against HSV-1 and HSV-2 at 1.0 and 10 jiM. 5-COOH-2'-dUrd showed no antiviral activity against either HSV-1 or HSV-2 at either of the concentrations tested (data not shown), whereas 1.0 uM F3dThd reduced the number of plaque-forming units of HSV-1 by 99% and that of HSV-2 by 95%.
Inhibition of HSV-1 and HEp-2 dTk. dTk (EC 2.7.1.21) phosphorylates dThd at the 5' position using ATP as the phosphoryl donor. Subsequent phosphorylation to the nucleoside triphosphate is followed by incorporation into DNA (2). dTk is required for the metabolic conversion of F3dThd to the nucleoside 5'-monophosphate. This allows subsequent phosphorylation to 5'-di-and triphosphates with incorporation into DNA. F3dThd is a potent competitive inhibitor of dThd for HEp-2 cell and HSV-1-induced dTk (Wigdahl and Parkhurst, Abstr. Annu. Meet. Am. Soc. MicrobioL 1977, S166, p. 306). 5-COOH-2'-dUrd was tested as an inhibitor of cellular and HSV-1-induced dTk. Experiments (Fig. 3) indicate essentially no inhibition of either enzyme by 5-COOH-2'-dUrd, suggesting that phosphorylation of 5-COOH-2'-dUrd by dTk is not an essential prerequisite to cytotoxicity. DISCUSSION Studies of the biological and pharmaceutical stability of most drugs must include preliminary investigations into the effects of physical and chemical conditions, such as temperature and pH. Investigations into the pharmaceutical stability of F3dThd were reported by Nestler and Garrett in 1968 (12) . These studies established that the stability of F3dThd was dependent on temperature and pH. These workers identified the primary solvolysis product of F3dThd as 5-COOH-2'-dUrd. They also established that this solvolysis proceeded via a hydroxyl ion attack on the 5-trifluoromethyl group (12) . This hydrolysis proceeds through a difluoro and a hypothetical monofluoro derivative of F3dThd before complete hydrolysis to 5-COOH-2'-dUrd (12) .
The results reported herein establish rate constants and half-lives for the hydrolysis of F3dThd in PBS at physiologically achievable pH's and temperature and indicate that this reaction proceeds via first-order kinetics. These results are in agreement with those reported by Nestler and Garrett (12) , whose conditions were more vigorous.
Investigations of the biological activity of the hydrolysis product of F3dThd, 5-COOH-2'-dUrd, have demonstrated that 5-COOH-2'-dUrd is markedly cytotoxic to HEp-2 cells at concentrations between 10 and 100 ,uM. Toxicity reversal studies with intermediates in the de novo pyrimidine biosynthetic pathway and other pyrimidines indicate that only a combination of uridine, dThd, and deoxycytidine could reverse 5-COOH-2'-dUrd-induced toxicity by 90%. This information served to localize the site of 5-COOH-2'-dUrd toxicity to reactions in the de novo pyrimidine pathway occurring before uridine 5'-phosphate. Inhibition (16) . Attempts to rigorously establish the site of action of 5-COOH-2'-dUrd must include kinetic investigations of the interaction of this compound with both activities of complex U.
Investigations were also performed to establish whether or not 5-COOH-2'-dUrd could be phosphorylated by HEp-2 cell or HSV-1-induced dTk. This possibility was examined because dTk is required for the metabolic activation of the parent compound, F3dThd. Our studies show, however, that neither cellular nor virus-induced dTk was inhibited by 5-COOH-2'-dUrd. 
